A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
- PMID: 9533527
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
Abstract
LY231514 is a novel antifolate that principally inhibits thymidylate synthase, but with additional folate-dependent enzyme targets. A Phase I study of single-agent LY231514 administered as a daily i.v. infusion over 10 minutes for 5 days, repeated every 3 weeks, was conducted to evaluate the maximum tolerated dose, pharmacokinetic profile, and antitumor activity of the drug using this schedule. Thirty-eight patients with advanced malignancies that were refractory or not amenable to standard therapy were treated with a total of 116 courses of LY231514, escalating treatment doses through 10 dose levels, from 0.2-5.2 mg/m2/day. No objective clinical responses were observed, although minor antitumor activity not fulfilling the response criteria was seen in three patients. A maximum tolerated dose of 4.0 mg/m2/day was determined, with neutropenia as the predominant dose-limiting toxicity. Reversible disturbances of liver biochemistry, fulfilling the protocol definitions of dose-limiting toxicity, were also observed. Other toxicities included diarrhea, mucositis, skin rash, and fatigue. Pharmacokinetic studies were performed at all treatment levels. Analysis showed a linear relation between administered dose and both maximum plasma concentration (Cmax) and area under the plasma concentration/time curve. The drug was cleared with a day 1 total body clearance of 108.9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h. When given by this schedule, LY231514 is tolerable, and Phase II studies are in progress.
Similar articles
-
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.Cancer Chemother Pharmacol. 1999;44(5):372-80. doi: 10.1007/s002800050992. Cancer Chemother Pharmacol. 1999. PMID: 10501910 Clinical Trial.
-
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.J Clin Oncol. 1995 Nov;13(11):2842-50. doi: 10.1200/JCO.1995.13.11.2842. J Clin Oncol. 1995. PMID: 7595747 Clinical Trial.
-
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.Clin Cancer Res. 2001 Jul;7(7):1901-11. Clin Cancer Res. 2001. PMID: 11448903 Clinical Trial.
-
Overview of phase I trials of multitargeted antifolate (MTA, LY231514).Semin Oncol. 1999 Apr;26(2 Suppl 6):82-8. Semin Oncol. 1999. PMID: 10598560 Review.
-
Pemetrexed: a multitargeted antifolate.Clin Ther. 2005 Sep;27(9):1343-82. doi: 10.1016/j.clinthera.2005.09.010. Clin Ther. 2005. PMID: 16291410 Review.
Cited by
-
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.Drugs. 2022 Jan;82(1):15-32. doi: 10.1007/s40265-021-01654-3. Epub 2021 Dec 11. Drugs. 2022. PMID: 34894338 Review.
-
Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.Drug Saf. 2021 Dec;44(12):1271-1281. doi: 10.1007/s40264-021-01135-2. Epub 2021 Nov 6. Drug Saf. 2021. PMID: 34741752 Review.
-
Update on recent key publications in lung oncology: picking up speed.Eur Respir Rev. 2021 Jul 13;30(161):200300. doi: 10.1183/16000617.0300-2020. Print 2021 Sep 30. Eur Respir Rev. 2021. PMID: 34261741 Free PMC article.
-
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis.Clin Pharmacokinet. 2021 May;60(5):649-654. doi: 10.1007/s40262-020-00972-1. Epub 2021 Jan 9. Clin Pharmacokinet. 2021. PMID: 33420970 Free PMC article.
-
A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit.Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2973-2978. doi: 10.22034/APJCP.2018.19.10.2973. Asian Pac J Cancer Prev. 2018. PMID: 30362335 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources